NCT01868451 - Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Hodgkin Lymphoma

Interventions

DRUG

Brentuximab vedotin (SGN-35)

DRUG

Doxorubicin HCL

DRUG

Vinblastine Sulfate

DRUG

Dacarbazine

RADIATION

Involved-Site Radiation Therapy (ISRT)

PROCEDURE

Interim PET

RADIATION

consolidation volume RT (CVRT)

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

91010

City of Hope, Duarte

94305-5408

Stanford University Medical Center, Stanford

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

University of Rochester Medical Center, Rochester

All Listed Sponsors

collaborator

Seagen Inc.

INDUSTRY

collaborator

University of Rochester

OTHER

collaborator

City of Hope Medical Center

OTHER

collaborator

Stanford University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER